Synthesis, characterization, antioxidant, and anticancer studies of 6-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-3-[(2-naphthyloxy) methyl][1,2,4] triazolo[3,4-b][1,3,4]thiadiazole in HepG2 cell lines

dc.contributor.authorDhanya, D.
dc.contributor.authorIsloor, A.M.
dc.contributor.authorShetty, P.
dc.contributor.authorSatyamoorthy, K.
dc.contributor.authorPrasad, A.S.B.
dc.date.accessioned2026-02-05T09:35:45Z
dc.date.issued2011
dc.description.abstractTriazolo- thiadiazoles exhibit a variety of pharmacological properties, due to their cytotoxicity. In continuation of a previous study on triazolo-thiadiazoles, the authors have synthesized a new thiadiazole, 6-[3-(4-chlorophenyl)- 1-H-pyrazol-4-yl]-3-[(2-naphthyloxy)methyl] [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole (CPNT), which was further characterized by advanced spectral techniques and elemental analysis. The compound exhibited a dose-dependent cytotoxic effect on hepatocellular carcinoma cell line, HepG2 with very low IC<inf>50</inf> value of 0.8 ?g/ml in 24 h when compared with standard drug, doxorubicin. Incorporation of [3H] thymidine in conjunction with cell cycle analysis suggested that CPNT inhibited the growth of HepG2 cells. Flow cytometric studies revealed more percentage of cells in subG1 phase, indicating apoptosis, which was further confirmed through chromatin condensation studies by Hoechst staining. In vitro antioxidant activity of CPNT was determined by DPPH and ABTS free radical scavenging assays which revealed increasing scavenging activity with increasing concentration of the compound when compared with reference ascorbic acid. © Springer Science+Business Media, LLC 2010.
dc.identifier.citationMedicinal Chemistry Research, 2011, 20, 7, pp. 1074-1080
dc.identifier.issn10542523
dc.identifier.urihttps://doi.org/10.1007/s00044-010-9436-9
dc.identifier.urihttps://idr.nitk.ac.in/handle/123456789/27192
dc.subject6 [3 (4 chlorophenyl) 1h pyrazol 4 yl] 3 [(2 naphthyloxy)methyl][1,2,4]triazolo[3,4 b][1,3,4]thiadiazole
dc.subjectdoxorubicin
dc.subjectthiadiazole derivative
dc.subjectthymidine
dc.subjectunclassified drug
dc.subjectantineoplastic activity
dc.subjectantioxidant activity
dc.subjectapoptosis
dc.subjectarticle
dc.subjectcancer inhibition
dc.subjectcell cycle G1 phase
dc.subjectcell strain HepG2
dc.subjectchromatin condensation
dc.subjectcontrolled study
dc.subjectcytotoxicity
dc.subjectdrug structure
dc.subjectdrug synthesis
dc.subjectflow cytometry
dc.subjectIC 50
dc.titleSynthesis, characterization, antioxidant, and anticancer studies of 6-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-3-[(2-naphthyloxy) methyl][1,2,4] triazolo[3,4-b][1,3,4]thiadiazole in HepG2 cell lines

Files

Collections